Brexogen Signs Landmark Licensing Agreement with BMI Korea for Exosome Therapeutic

• Brexogen has entered a technology transfer and licensing agreement with BMI Korea for BxC-I17e, an exosome-based injectable therapeutic.

• The deal includes a KRW 3 billion (USD 2.3 million) upfront payment, milestone-based payments, and double-digit royalties on sales.

Brexogen, a biotechnology company specialising in exosome-based therapeutics, has signed a licensing and technology transfer agreement with BMI Korea for BxC-I17e. The agreement represents the first major licensing deal for an exosome therapeutic in Korea and marks a key milestone in the commercialisation of exosome-based medicines.

BxC-I17e, a leading asset in Brexogen’s pipeline, is currently in clinical trials in the United States for atopic dermatitis. Under the agreement, BMI Korea has secured rights to develop the therapeutic for indications beyond immunological diseases, covering both domestic and key export markets. While financial terms remain confidential, Brexogen will receive a non-refundable KRW 3 billion (USD 2.3 million) upfront payment, along with milestone payments linked to regulatory and commercial progress and double-digit percentage royalties on net sales. The company will also benefit from future licensing revenues should BMI Korea pursue further out-licensing.

BMI Korea, a pharmaceutical company with annual revenues exceeding KRW 100 billion (USD 77 million), specialises in prescription drugs, biologics, and medical devices. The company operates large-scale contract manufacturing (CMO) facilities in Jeju and Osong, Chungbuk. As part of the partnership, BxC-I17e will be manufactured at BMI Korea’s facilities to support clinical and commercial supply.

“Partnering with BMI Korea is a significant step forward for Brexogen,” said a Brexogen representative. “Their robust pharmaceutical manufacturing expertise provides a strong foundation for the commercialisation of BxC-I17e, allowing us to accelerate market entry while ensuring high-quality production.”

Founded in 2019, Brexogen has pioneered Natural Biomacromolecule Cargo-Controlled Exosome Technology, with applications in therapeutics, medical devices, and aesthetics. The company is preparing for its KOSDAQ listing in 2026. The partnership with BMI Korea is expected to drive the adoption of exosome-based therapies and contribute to advancements in regenerative medicine.